Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Zasocitinib by Takeda Pharmaceutical for Ulcerative Colitis: Likelihood of Approval
Zasocitinib is under clinical development by Takeda Pharmaceutical and currently in Phase II for Ulcerative Colitis. According to GlobalData, Phase...
Zasocitinib by Takeda Pharmaceutical for Generalized Pustular Psoriasis (GPP): Likelihood of Approval
Zasocitinib is under clinical development by Takeda Pharmaceutical and currently in Phase III for Generalized Pustular Psoriasis (GPP). According to...
Zasocitinib by Takeda Pharmaceutical for Crohn's Disease (Regional Enteritis): Likelihood of Approval
Zasocitinib is under clinical development by Takeda Pharmaceutical and currently in Phase II for Crohn's Disease (Regional Enteritis). According to...
Zasocitinib by Takeda Pharmaceutical for Plaque Psoriasis (Psoriasis Vulgaris): Likelihood of Approval
Zasocitinib is under clinical development by Takeda Pharmaceutical and currently in Phase III for Plaque Psoriasis (Psoriasis Vulgaris). According to...
Zasocitinib by Takeda Pharmaceutical for Psoriatic Arthritis: Likelihood of Approval
Zasocitinib is under clinical development by Takeda Pharmaceutical and currently in Phase II for Psoriatic Arthritis. According to GlobalData, Phase...
Risk adjusted net present value: What is the current valuation of Takeda Pharmaceutical's Zasocitinib?
Zasocitinib is a small molecule commercialized by Takeda Pharmaceutical, with a leading Phase III program in Plaque Psoriasis (Psoriasis Vulgaris)....